EyePoint Pharmaceuticals announced the US commercially launch of Yutiq, a 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The company has also launched EyePoint Assist, a program to ensure access to Yutiq for eligible patients in need of financial assistance.
“We are pleased to announce the availability of Yutiq in the US, which is an advancement in the treatment of chronic, noninfectious posterior segment uveitis,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “Yutiq is the first FDA-approved fluocinolone acetonide micro-insert to address this serious condition that is the third leading cause of blindness in the country. One micro-insert of Yutiq has the ability to deliver up to 3 years of fluocinolone acetonide, a commonly used steroid, with continuous dosing that avoids the peaks and valleys of local corticosteroids, the current standard of care. In clinical studies, Yutiq significantly reduced the number of inflammatory uveitis eye flares, which can lead to blindness. We are proud to bring this innovative treatment to patients to address this high unmet need.”
Yutiq utilizes the company’s Durasert drug delivery technology and is an intravitreal micro-insert containing 0.18 mg of fluocinolone acetonide, designed to release consistently for up to 36 months. Yutiq is supplied in a sterile single-dose preloaded applicator that can be administered in the physician’s office. In phase 3 clinical trials, Yutiq significantly reduced the rate of recurrent uveitis flares versus sham, and the most common adverse reactions reported were cataract development and increase in IOP.